IP Library Granted Patent US 9,193,737
Granted Patent B2
US 9,193,737 · App. 14/533,522 · Granted Nov 24, 2015

Production of 6-hydroxy morphinans without the isolation of intermediates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,193,737
App. No.
14/533,522
Granted
Nov 24, 2015
Kind
B2
Abstract

The present invention provides a process for preparing a saturated 6,14-dihydroxy morphinan. The process comprises contacting an unsaturated 6-O-hydrocarbyl morphinan with hydrogen peroxide and an organic acid to form an unsaturated 6-keto-14-hydroxy morphinan. The unsaturated 6-keto-14-hydroxy morphinan is contacted with a first reducing agent to form an unsaturated 6,14-dihydroxy morphinan, and the unsaturated 6,14-dihydroxy morphinan is contacted with a second reducing agent to form the saturated 6,14-dihydroxy morphinan.

Claims (36)

1. A process for preparing a compound of Formula (IV) from a compound of Formula (I), comprising:

(a) contacting the compound of Formula (I) with hydrogen peroxide and a compound of formula HOOCR 18 to form a compound of Formula (II);

(b) contacting the compound of Formula (II) with a first reducing agent to form a compound of Formula (III); and

(c) contacting the compound of Formula (III) with a second reducing agent to form the compound of Formula (IV) according to the following reaction scheme:

wherein:

A is oxygen;

R is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, amino, halogen, {—}OH, {—}OR 1611 , {—}SH, {—}SR 1611 , {—}NHR 1611 , {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl;

R 5 , R 7 ,R 8 , R 9 , R 10a ,R 10b , R 15a , R 15b ,R 16a , and R 16b are independently selected from the group consisting of hydrogen, amino, halogen, {—}OH, {—}OR 1611 , {—}SH, {—}SR 1611 , {—}NHR 1611 , {—}NR 1611 R 1612 , hydrocarbyl, and substituted hydrocarbyl; wherein any pair of R #a and R #b wherein # is any one of 10, 15, and 16, optionally together form a moiety chosen from the group consisting of {═}O, {═}S, {=}CH 2 , and {═}NR 1612 ;

R 6 , R 1611 , and R 1612 are independently selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

R 18 is selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl.

2. The process of claim 1 , wherein

R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted aryl;

R 1 and R 2 are independently selected from the group consisting of hydrogen, amino, amine, halo, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, aryl, substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted aryl;

R 3 is selected from the group consisting of hydroxy, alkoxy, hydrocarbyloxy, and substituted hydrocarbyloxy;

R 6 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted aryl;

R 5 , R 7 , R 8 , R 9 , R 10a , R 15a , R 15b ,R 16a , and R 16b are independently selected from the group consisting of hydrogen, amino, amine, halo, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, aryl, substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted aryl; and

R 18 is selected from the group consisting of hydrogen, alkyl, aryl, substituted alkyl, and substituted aryl.

3. The process of claim 2 , wherein; R is selected from the group consisting of hydrogen, methyl, cyclopropyl methyl, cyclobutyl methyl, and allyl; R 1 , R 2 , R 5 , R 7 , R 8 , R 9 , R 10a , R 10b , R 15a , R 15b , R 16a , and R 16b if present, are hydrogen; R 3 is selected from the group consisting of hydroxy, alkoxy, aryloxy, substituted aryloxy, and protected hydroxy; R 6 is selected from the group consisting of alkyl and aryl; and R 18 is selected from the group consisting of hydrogen, methyl, phenyl, and substituted phenyl.

4. The process of claim 1 , wherein the mole to mole ratio of the compound of Formula (I) to hydrogen peroxide to the compound comprising formula HOOCR 18 is from about 1:0.1:0.2 to about 1:11:40.

5. The process of claim 1 , wherein the first reducing agent comprises a borohydride.

6. The process of claim 5 , wherein the mole to mole ratio of the compound of Formula (II) to hydride from the first reducing agent is from about 1:0.15 to about 1:25.

7. The process of claim 1 , wherein the second reducing agent is selected from the group consisting of a hydrogen transfer reagent, a combination of a hydrogen transfer reagent and a metal catalyst, and hydrogen and a metal catalyst.

8. The process of claim 1 , wherein the second reducing agent is a hydrogen transfer reagent, and the hydrogen transfer reagent is used in the presence of a transition metal catalyst.

9. The process of claim 8 , wherein the mole to mole ratio of the compound of Formula (III) to the hydrogen transfer reagent to the transition metal catalyst is from about 1:0.5:0.0004 to about 1:10:0.08.

10. The process of claim 1 , wherein the process is conducted in the presence of at least one polar protic solvent; and the volume to mass ratio of the solvent to the compound of Formula (I) is from about 0.5:1 to about 100:1.

11. The process of claim 1 , wherein the process is conducted at a temperature from about 0° C. to about 100° C.

12. The process of claim 1 , wherein steps (a), (b), and (c) are conducted in a single reaction pot without isolation of the compounds of Formula (II) or Formula (III).

13. The process of claim 1 , further comprising, after step (c), adjusting the pH to greater than about 8.7 to precipitate the compound of Formula (IV).

14. The process of claim 1 , further comprising removing the hydroxyl group from C-14 of the compound of Formula (IV).

15. The process of claim 1 , wherein the compounds of Formulas (I), (II), (III), and (IV) independently have an optical activity of (−) or (+); and the configuration of C-5, C-13, C-14, and C-9, respectively, is RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, or SSSS, provided that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

16. The process of claim 1 , wherein the hydroxy group on C-6 of the compounds of Formulas (III) or (IV) has an alpha isomer to beta isomer ratio of at least 90:10.

17. The process of claim 3 , wherein R 18 is hydrogen; the first reducing agent is sodium borohydride or sodium triacetoxyborohydride; the second reducing agent is a hydrogen transfer agent which is used in the presence of a transition metal catalyst, and the hydrogen transfer agent is formic acid.

18. The process of claim 17 , wherein the mole to mole ratio of the compound of Formula (I) to hydrogen peroxide to the compound of formula HOOCR 18 is from about 1:0.6:1 to about 1:2.2:8; the mole to mole ratio of the compound of Formula (II) to hydride from the first reducing agent is from about 1:0.7 to about 1:5; the mole to mole ratio of the compound of Formula (III) to the hydrogen transfer reagent to the transition metal catalyst is from about 1:0.1:0.002 to about 1:1:0.02.

19. The process of claim 18 , wherein the process is conducted in the presence of at least one polar protic solvent; and the volume to mass ratio of the solvent to the compound of Formula (I) is from about 1:1 to about 20:1, and the process is conducted at a temperature from about 0° C. to about 70° C.

20. The process of claim 19 , further comprising removing the hydroxyl group from C-14 of the compound of Formula (IV).

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 039237, FRAME 0147 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0902 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jul 1, 2016
From: MALLINCKRODT LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 039237/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2015
From: WANG, PETER X.; JIANG, TAO
To: MALLINCKRODT LLC
Reel/Frame 035640/0272 →